This is another condition where there is a great unmet need for new treatments.  We have participated in a phase 1b study of the anti-CD20 small modular immunopharmaceutical TRU-15 for polymyositis and dermatomyositis.   In addition, Dr. Eggebeen, who has advanced training in myositis care at the University of Pittsburg, had done translational research linking myositis associated antibodies to the development of intersitial lung disease.  Subsequently Dr. Eggebeen was a principle investigator in the National Institute of Health funded, first of it kind trial the “Rituximab in Myositis Study”.